Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 143

1.

Clinicopathological characteristics of glomeruloid architecture in prostate cancer.

Hollemans E, Verhoef EI, Bangma CH, Rietbergen J, Osanto S, Pelger RCM, van Wezel T, van der Poel H, Bekers E, Helleman J, Roobol MJ, van Leenders GJLH.

Mod Pathol. 2020 Feb 20. doi: 10.1038/s41379-020-0507-2. [Epub ahead of print]

PMID:
32080350
2.

Optimizing mutation and fusion detection in Non-Small Cell Lung Cancer by sequential DNA and RNA sequencing.

Cohen D, Hondelink LM, Solleveld-Westerink N, Uljee SM, Ruano D, Cleton-Jansen AM, Thüsen JV, Ramai S, Postmus P, Graadt van Roggen JF, Hoppe B, Clahsen P, Maas K, Ahsmann E, Heuvel AT, Smedts F, Nanno van Rossem R, van Wezel T.

J Thorac Oncol. 2020 Jan 31. pii: S1556-0864(20)30093-9. doi: 10.1016/j.jtho.2020.01.019. [Epub ahead of print]

3.

Apparent Lack of BRAF V600E Derived HLA Class I Presented Neoantigens Hampers Neoplastic Cell Targeting by CD8+ T Cells in Langerhans Cell Histiocytosis.

Kemps PG, Zondag TC, Steenwijk EC, Andriessen Q, Borst J, Vloemans S, Roelen DL, Voortman LM, Verdijk RM, van Noesel CJM, Cleven AHG, Hawkins C, Lang V, de Ru AH, Janssen GMC, Haasnoot GW, Franken KLMC, van Eijk R, Solleveld-Westerink N, van Wezel T, Egeler RM, Beishuizen A, van Laar JAM, Abla O, van den Bos C, van Veelen PA, van Halteren AGS.

Front Immunol. 2020 Jan 10;10:3045. doi: 10.3389/fimmu.2019.03045. eCollection 2019.

4.

The complexity of screening PMS2 in DNA isolated from formalin-fixed paraffin-embedded material.

Jansen AML, Tops CMJ, Ruano D, van Eijk R, Wijnen JT, Ten Broeke S, Nielsen M, Hes FJ, van Wezel T, Morreau H.

Eur J Hum Genet. 2020 Mar;28(3):333-338. doi: 10.1038/s41431-019-0527-x. Epub 2019 Oct 15.

PMID:
31616036
5.

The missing heritability of familial colorectal cancer.

Schubert SA, Morreau H, de Miranda NFCC, van Wezel T.

Mutagenesis. 2019 Oct 12. pii: gez027. doi: 10.1093/mutage/gez027. [Epub ahead of print]

PMID:
31605533
6.

A unique case of two somatic APC mutations in an early onset cribriform-morular variant of papillary thyroid carcinoma and overview of the literature.

Aydemirli MD, van der Tuin K, Hes FJ, van den Ouweland AMW, van Wezel T, Kapiteijn E, Morreau H.

Fam Cancer. 2020 Jan;19(1):15-21. doi: 10.1007/s10689-019-00146-4.

PMID:
31598872
7.

Declining detection rates for APC and biallelic MUTYH variants in polyposis patients, implications for DNA testing policy.

Terlouw D, Suerink M, Singh SS, Gille HJJP, Hes FJ, Langers AMJ, Morreau H, Vasen HFA, Vos YJ, van Wezel T, Tops CM, Ten Broeke SW, Nielsen M.

Eur J Hum Genet. 2020 Feb;28(2):222-230. doi: 10.1038/s41431-019-0509-z. Epub 2019 Sep 16.

PMID:
31527860
8.

Targeted Treatment Options of Recurrent Radioactive Iodine Refractory Hürthle Cell Cancer.

Aydemirli MD, Corver W, Beuk R, Roepman P, Solleveld-Westerink N, van Wezel T, Kapiteijn E, Morreau H.

Cancers (Basel). 2019 Aug 15;11(8). pii: E1185. doi: 10.3390/cancers11081185.

9.

MYD88 mutations identify a molecular subgroup of diffuse large B-cell lymphoma with an unfavorable prognosis.

Vermaat JS, Somers SF, de Wreede LC, Kraan W, de Groen RAL, Schrader AMR, Kerver ED, Scheepstra CG, Berenschot H, Deenik W, Wegman J, Broers R, de Boer JD, Nijland M, van Wezel T, Veelken H, Spaargaren M, Cleven AH, Kersten MJ, Pals ST.

Haematologica. 2020 Jan 31;105(2):424-434. doi: 10.3324/haematol.2018.214122. Print 2020.

10.

Targeted next generation sequencing screening of Lynch syndrome in Tunisian population.

Ben Sghaier R, Jansen AML, Bdioui A, Van Wezel T, Ksiaa M, Elgolli L, Ben Fatma L, Ben Ahmed S, Azzouz MM, Hellara O, Elghali A, Darbel F, Skandrani K, Mokkni M, Gdissa A, Ltaief R, Saad A, Hmila F, Gribaa M, Morreau H.

Fam Cancer. 2019 Jul;18(3):343-348. doi: 10.1007/s10689-019-00130-y.

PMID:
31114938
11.

Allelic Switching of DLX5, GRB10, and SVOPL during Colorectal Cancer Tumorigenesis.

Boot A, Oosting J, Doorn S, Ouahoud S, Ventayol Garcia M, Ruano D, Morreau H, van Wezel T.

Int J Genomics. 2019 Apr 10;2019:1287671. doi: 10.1155/2019/1287671. eCollection 2019.

12.

Recommendations for the clinical interpretation and reporting of copy number gains using gene panel NGS analysis in routine diagnostics.

Eijkelenboom A, Tops BBJ, van den Berg A, van den Brule AJC, Dinjens WNM, Dubbink HJ, Ter Elst A, Geurts-Giele WRR, Groenen PJTA, Groenendijk FH, Heideman DAM, Huibers MMH, Huijsmans CJJ, Jeuken JWM, van Kempen LC, Korpershoek E, Kroeze LI, de Leng WWJ, van Noesel CJM, Speel EM, Vogel MJ, van Wezel T, Nederlof PM, Schuuring E, Ligtenberg MJL.

Virchows Arch. 2019 Jun;474(6):673-680. doi: 10.1007/s00428-019-02555-3. Epub 2019 Mar 19.

13.

Low frequency of POLD1 and POLE exonuclease domain variants in patients with multiple colorectal polyps.

Elsayed FA, Tops CMJ, Nielsen M, Ruano D, Vasen HFA, Morreau H, J Hes F, van Wezel T.

Mol Genet Genomic Med. 2019 Apr;7(4):e00603. doi: 10.1002/mgg3.603. Epub 2019 Mar 2.

14.

Mutational Signature Analysis Reveals NTHL1 Deficiency to Cause a Multi-tumor Phenotype.

Grolleman JE, de Voer RM, Elsayed FA, Nielsen M, Weren RDA, Palles C, Ligtenberg MJL, Vos JR, Ten Broeke SW, de Miranda NFCC, Kuiper RA, Kamping EJ, Jansen EAM, Vink-Börger ME, Popp I, Lang A, Spier I, Hüneburg R, James PA, Li N, Staninova M, Lindsay H, Cockburn D, Spasic-Boskovic O, Clendenning M, Sweet K, Capellá G, Sjursen W, Høberg-Vetti H, Jongmans MC, Neveling K, Geurts van Kessel A, Morreau H, Hes FJ, Sijmons RH, Schackert HK, Ruiz-Ponte C, Dymerska D, Lubinski J, Rivera B, Foulkes WD, Tomlinson IP, Valle L, Buchanan DD, Kenwrick S, Adlard J, Dimovski AJ, Campbell IG, Aretz S, Schindler D, van Wezel T, Hoogerbrugge N, Kuiper RP.

Cancer Cell. 2019 Feb 11;35(2):256-266.e5. doi: 10.1016/j.ccell.2018.12.011.

15.

Targetable gene fusions identified in radioactive iodine refractory advanced thyroid carcinoma.

van der Tuin K, Ventayol Garcia M, Corver WE, Khalifa MN, Ruano Neto D, Corssmit EPM, Hes FJ, Links TP, Smit JWA, Plantinga TS, Kapiteijn E, van Wezel T, Morreau H.

Eur J Endocrinol. 2019 Apr 1;180(4):235-241. doi: 10.1530/EJE-18-0653.

PMID:
30668525
16.

Clinical and Molecular Characteristics May Alter Treatment Strategies of Thyroid Malignancies in DICER1 Syndrome.

van der Tuin K, de Kock L, Kamping EJ, Hannema SE, Pouwels MM, Niedziela M, van Wezel T, Hes FJ, Jongmans MC, Foulkes WD, Morreau H.

J Clin Endocrinol Metab. 2019 Feb 1;104(2):277-284. doi: 10.1210/jc.2018-00774.

PMID:
30260442
17.

Molecular Analysis of Gene Fusions in Bone and Soft Tissue Tumors by Anchored Multiplex PCR-Based Targeted Next-Generation Sequencing.

Lam SW, Cleton-Jansen AM, Cleven AHG, Ruano D, van Wezel T, Szuhai K, Bovée JVMG.

J Mol Diagn. 2018 Sep;20(5):653-663. doi: 10.1016/j.jmoldx.2018.05.007. Epub 2018 Aug 20.

18.

HLA-G protein expression in colorectal cancer evaluated by immunohistochemistry and western blot analysis: Its expression characteristics remain enigmatic.

Swets M, Wouters A, Krijgsman D, van Vlierberghe RLP, Boot A, van Eendenburg JD, van Wezel T, Gelderblom H, van de Velde CJH, van den Elsen PJ, Kuppen PJK.

Clin Immunol. 2018 Sep;194:80-86. doi: 10.1016/j.clim.2018.07.005. Epub 2018 Jul 10.

PMID:
30006120
19.

Validation and Implementation of BRCA1/2 Variant Screening in Ovarian Tumor Tissue.

de Jonge MM, Ruano D, van Eijk R, van der Stoep N, Nielsen M, Wijnen JT, Ter Haar NT, Baalbergen A, Bos MEMM, Kagie MJ, Vreeswijk MPG, Gaarenstroom KN, Kroep JR, Smit VTHBM, Bosse T, van Wezel T, van Asperen CJ.

J Mol Diagn. 2018 Sep;20(5):600-611. doi: 10.1016/j.jmoldx.2018.05.005. Epub 2018 Jun 21.

20.

Molecular Background of Colorectal Tumors From Patients With Lynch Syndrome Associated With Germline Variants in PMS2.

Ten Broeke SW, van Bavel TC, Jansen AML, Gómez-García E, Hes FJ, van Hest LP, Letteboer TGW, Olderode-Berends MJW, Ruano D, Spruijt L, Suerink M, Tops CM, van Eijk R, Morreau H, van Wezel T, Nielsen M.

Gastroenterology. 2018 Sep;155(3):844-851. doi: 10.1053/j.gastro.2018.05.020. Epub 2018 Jul 29.

PMID:
29758216
21.

RNA analysis of cancer predisposing genes in formalin-fixed paraffin-embedded tissue determines aberrant splicing.

Jansen AM, van der Klift HM, Roos MA, van Eendenburg JD, Tops CM, Wijnen JT, Hes FJ, Morreau H, van Wezel T.

Eur J Hum Genet. 2018 Aug;26(8):1143-1150. doi: 10.1038/s41431-018-0153-z. Epub 2018 Apr 30.

22.

Evidence for genetic association between chromosome 1q loci and predisposition to colorectal neoplasia.

Schubert SA, Ruano D, Elsayed FA, Boot A, Crobach S, Sarasqueta AF, Wolffenbuttel B, van der Klauw MM, Oosting J, Tops CM, van Eijk R, Vasen HF, Vossen RH, Nielsen M, Castellví-Bel S, Ruiz-Ponte C, Tomlinson I, Dunlop MG, Vodicka P, Wijnen JT, Hes FJ, Morreau H, de Miranda NF, Sijmons RH, van Wezel T.

Br J Cancer. 2018 Jan;118(2):e4. doi: 10.1038/bjc.2017.380. Epub 2017 Oct 12. No abstract available.

23.

SNP association study in PMS2-associated Lynch syndrome.

Ten Broeke SW, Elsayed FA, Pagan L, Olderode-Berends MJW, Garcia EG, Gille HJP, van Hest LP, Letteboer TGW, van der Kolk LE, Mensenkamp AR, van Os TA, Spruijt L, Redeker BJW, Suerink M, Vos YJ, Wagner A, Wijnen JT, Steyerberg EW, Tops CMJ, van Wezel T, Nielsen M.

Fam Cancer. 2018 Oct;17(4):507-515. doi: 10.1007/s10689-017-0061-3.

24.

Excluding Lynch syndrome in a female patient with metachronous DNA mismatch repair deficient colon- and ovarian cancer.

Crobach S, Jansen AML, Ligtenberg MJL, Koopmans M, Nielsen M, Hes FJ, Wijnen JT, Dinjens WNM, van Wezel T, Morreau H.

Fam Cancer. 2018 Jul;17(3):415-420. doi: 10.1007/s10689-017-0055-1.

25.

Methylation associated transcriptional repression of ELOVL5 in novel colorectal cancer cell lines.

Boot A, Oosting J, van Eendenburg JDH, Kuppen PJK, Morreau H, van Wezel T.

PLoS One. 2017 Sep 20;12(9):e0184900. doi: 10.1371/journal.pone.0184900. eCollection 2017.

26.

Use of CRISPR-modified human stem cell organoids to study the origin of mutational signatures in cancer.

Drost J, van Boxtel R, Blokzijl F, Mizutani T, Sasaki N, Sasselli V, de Ligt J, Behjati S, Grolleman JE, van Wezel T, Nik-Zainal S, Kuiper RP, Cuppen E, Clevers H.

Science. 2017 Oct 13;358(6360):234-238. doi: 10.1126/science.aao3130. Epub 2017 Sep 14.

27.

Genomic Characterization of Vulvar (Pre)cancers Identifies Distinct Molecular Subtypes with Prognostic Significance.

Nooij LS, Ter Haar NT, Ruano D, Rakislova N, van Wezel T, Smit VTHBM, Trimbos BJBMZ, Ordi J, van Poelgeest MIE, Bosse T.

Clin Cancer Res. 2017 Nov 15;23(22):6781-6789. doi: 10.1158/1078-0432.CCR-17-1302. Epub 2017 Sep 12.

28.

Evidence for genetic association between chromosome 1q loci and predisposition to colorectal neoplasia.

Schubert SA, Ruano D, Elsayed FA, Boot A, Crobach S, Sarasqueta AF, Wolffenbuttel B, van der Klauw MM, Oosting J, Tops CM, van Eijk R, Vasen HF, Vossen RH, Nielsen M, Castellví-Bel S, Ruiz-Ponte C, Tomlinson I, Dunlop MG, Vodicka P, Wijnen JT, Hes FJ, Morreau H, de Miranda NF, Sijmons RH, van Wezel T.

Br J Cancer. 2017 Sep 5;117(6):1215-1223. doi: 10.1038/bjc.2017.240. Epub 2017 Jul 25. Erratum in: Br J Cancer. 2018 Jan;118(2):e4.

29.

Chemosensitivity of BRCA1-Mutated Ovarian Cancer Cells and Established Cytotoxic Agents.

van Haaften C, van Eendenburg J, Boot A, Corver WE, Haans L, van Wezel T, Trimbos JB.

Int J Gynecol Cancer. 2017 Oct;27(8):1571-1578. doi: 10.1097/IGC.0000000000001052.

PMID:
28604461
30.

Statin Use After Diagnosis of Colon Cancer and Patient Survival.

Voorneveld PW, Reimers MS, Bastiaannet E, Jacobs RJ, van Eijk R, Zanders MMJ, Herings RMC, van Herk-Sukel MPP, Kodach LL, van Wezel T, Kuppen PJK, Morreau H, van de Velde CJH, Hardwick JCH, Liefers GJ.

Gastroenterology. 2017 Aug;153(2):470-479.e4. doi: 10.1053/j.gastro.2017.05.011. Epub 2017 May 13.

PMID:
28512021
31.

POLE and POLD1 screening in 155 patients with multiple polyps and early-onset colorectal cancer.

Esteban-Jurado C, Giménez-Zaragoza D, Muñoz J, Franch-Expósito S, Álvarez-Barona M, Ocaña T, Cuatrecasas M, Carballal S, López-Cerón M, Marti-Solano M, Díaz-Gay M, van Wezel T, Castells A, Bujanda L, Balmaña J, Gonzalo V, Llort G, Ruiz-Ponte C, Cubiella J, Balaguer F, Aligué R, Castellví-Bel S.

Oncotarget. 2017 Apr 18;8(16):26732-26743. doi: 10.18632/oncotarget.15810.

32.

Somatic POLE proofreading domain mutation, immune response, and prognosis in colorectal cancer: a retrospective, pooled biomarker study.

Domingo E, Freeman-Mills L, Rayner E, Glaire M, Briggs S, Vermeulen L, Fessler E, Medema JP, Boot A, Morreau H, van Wezel T, Liefers GJ, Lothe RA, Danielsen SA, Sveen A, Nesbakken A, Zlobec I, Lugli A, Koelzer VH, Berger MD, Castellví-Bel S, Muñoz J; Epicolon consortium, de Bruyn M, Nijman HW, Novelli M, Lawson K, Oukrif D, Frangou E, Dutton P, Tejpar S, Delorenzi M, Kerr R, Kerr D, Tomlinson I, Church DN.

Lancet Gastroenterol Hepatol. 2016 Nov;1(3):207-216. doi: 10.1016/S2468-1253(16)30014-0. Epub 2016 Jul 20.

PMID:
28404093
33.

The Influence of BRAF and KRAS Mutation Status on the Association between Aspirin Use and Survival after Colon Cancer Diagnosis.

Frouws MA, Reimers MS, Swets M, Bastiaannet E, Prinse B, van Eijk R, Lemmens VE, van Herk-Sukel MP, van Wezel T, Kuppen PJ, Morreau H, van de Velde CJ, Liefers GJ.

PLoS One. 2017 Jan 26;12(1):e0170775. doi: 10.1371/journal.pone.0170775. eCollection 2017.

34.

Linking uterine serous carcinoma to BRCA1/2-associated cancer syndrome: A meta-analysis and case report.

de Jonge MM, Mooyaart AL, Vreeswijk MP, de Kroon CD, van Wezel T, van Asperen CJ, Smit VT, Dekkers OM, Bosse T.

Eur J Cancer. 2017 Feb;72:215-225. doi: 10.1016/j.ejca.2016.11.028. Epub 2016 Dec 31. Review.

PMID:
28049106
35.

Tumor LINE-1 Methylation Level in Association with Survival of Patients with Stage II Colon Cancer.

Swets M, Zaalberg A, Boot A, van Wezel T, Frouws MA, Bastiaannet E, Gelderblom H, van de Velde CJ, Kuppen PJ.

Int J Mol Sci. 2016 Dec 27;18(1). pii: E36. doi: 10.3390/ijms18010036.

36.

Everolimus in Patients With Advanced Follicular-Derived Thyroid Cancer: Results of a Phase II Clinical Trial.

Schneider TC, de Wit D, Links TP, van Erp NP, van der Hoeven JJ, Gelderblom H, Roozen IC, Bos M, Corver WE, van Wezel T, Smit JW, Morreau H, Guchelaar HJ, Kapiteijn E.

J Clin Endocrinol Metab. 2017 Feb 1;102(2):698-707. doi: 10.1210/jc.2016-2525. Erratum in: J Clin Endocrinol Metab. 2017 Jun 1;102(6):2125.

PMID:
27870581
37.

Distinct Patterns of Somatic Mosaicism in the APC Gene in Neoplasms From Patients With Unexplained Adenomatous Polyposis.

Jansen AM, Crobach S, Geurts-Giele WR, van den Akker BE, Garcia MV, Ruano D, Nielsen M, Tops CM, Wijnen JT, Hes FJ, van Wezel T, Dinjens WN, Morreau H.

Gastroenterology. 2017 Feb;152(3):546-549.e3. doi: 10.1053/j.gastro.2016.10.040. Epub 2016 Nov 2.

PMID:
27816598
38.

Practical guidance for mismatch repair-deficiency testing in endometrial cancer.

Stelloo E, Jansen AML, Osse EM, Nout RA, Creutzberg CL, Ruano D, Church DN, Morreau H, Smit VTHBM, van Wezel T, Bosse T.

Ann Oncol. 2017 Jan 1;28(1):96-102. doi: 10.1093/annonc/mdw542.

39.

Targeted next-generation sequencing of FNA-derived DNA in pancreatic cancer.

Sibinga Mulder BG, Mieog JS, Handgraaf HJ, Farina Sarasqueta A, Vasen HF, Potjer TP, Swijnenburg RJ, Luelmo SA, Feshtali S, Inderson A, Vahrmeijer AL, Bonsing BA, van Wezel T, Morreau H.

J Clin Pathol. 2017 Feb;70(2):174-178. doi: 10.1136/jclinpath-2016-203928. Epub 2016 Sep 26.

PMID:
27672215
40.

Somatic mutation profiles in primary colorectal cancers and matching ovarian metastases: Identification of driver and passenger mutations.

Crobach S, Ruano D, van Eijk R, Schrumpf M; PALGA group, Fleuren G, van Wezel T, Morreau H.

J Pathol Clin Res. 2016 Apr 15;2(3):166-74. doi: 10.1002/cjp2.45. eCollection 2016 Jul.

41.

Whole Gene Capture Analysis of 15 CRC Susceptibility Genes in Suspected Lynch Syndrome Patients.

Jansen AM, Geilenkirchen MA, van Wezel T, Jagmohan-Changur SC, Ruano D, van der Klift HM, van den Akker BE, Laros JF, van Galen M, Wagner A, Letteboer TG, Gómez-García EB, Tops CM, Vasen HF, Devilee P, Hes FJ, Morreau H, Wijnen JT.

PLoS One. 2016 Jun 14;11(6):e0157381. doi: 10.1371/journal.pone.0157381. eCollection 2016.

42.

Imprinted survival genes preclude loss of heterozygosity of chromosome 7 in cancer cells.

Boot A, Oosting J, de Miranda NF, Zhang Y, Corver WE, van de Water B, Morreau H, van Wezel T.

J Pathol. 2016 Sep;240(1):72-83. doi: 10.1002/path.4756.

PMID:
27265324
43.

Promoter methylation and mRNA expression of HLA-G in relation to HLA-G protein expression in colorectal cancer.

Swets M, Seneby L, Boot A, van Wezel T, Gelderblom H, van de Velde CJ, van den Elsen PJ, Kuppen PJ.

Hum Immunol. 2016 Sep;77(9):764-72. doi: 10.1016/j.humimm.2016.05.023. Epub 2016 May 28.

PMID:
27245757
44.

Correspondence: SEMA4A variation and risk of colorectal cancer.

Kinnersley B, Chubb D, Dobbins SE, Frampton M, Buch S, Timofeeva MN, Castellví-Bel S, Farrington SM, Forsti A, Hampe J, Hemminki K, Hofstra RM, Northwood E, Palles C, Pinheiro M, Ruiz-Ponte C, Schafmayer C, Teixeira MR, Westers H, van Wezel T, Timothy Bishop D, Tomlinson I, Dunlop MG, Houlston RS.

Nat Commun. 2016 Mar 10;7:10611. doi: 10.1038/ncomms10611. No abstract available.

45.

Characterization of novel low passage primary and metastatic colorectal cancer cell lines.

Boot A, van Eendenburg J, Crobach S, Ruano D, Speetjens F, Calame J, Oosting J, Morreau H, van Wezel T.

Oncotarget. 2016 Mar 22;7(12):14499-509. doi: 10.18632/oncotarget.7391.

46.

Colorectal cancer risk variants at 8q23.3 and 11q23.1 are associated with disease phenotype in APC mutation carriers.

Ghorbanoghli Z, Nieuwenhuis MH, Houwing-Duistermaat JJ, Jagmohan-Changur S, Hes FJ, Tops CM, Wagner A, Aalfs CM, Verhoef S, Gómez García EB, Sijmons RH, Menko FH, Letteboer TG, Hoogerbrugge N, van Wezel T, Vasen HF, Wijnen JT.

Fam Cancer. 2016 Oct;15(4):563-70. doi: 10.1007/s10689-016-9877-5.

47.

(Secondary) solid tumors in thyroid cancer patients treated with the multi-kinase inhibitor sorafenib may present diagnostic challenges.

Schneider TC, Kapiteijn E, van Wezel T, Smit JWA, van der Hoeven JJM, Morreau H.

BMC Cancer. 2016 Jan 19;16:31. doi: 10.1186/s12885-016-2060-4.

48.

Combined mismatch repair and POLE/POLD1 defects explain unresolved suspected Lynch syndrome cancers.

Jansen AM, van Wezel T, van den Akker BE, Ventayol Garcia M, Ruano D, Tops CM, Wagner A, Letteboer TG, Gómez-García EB, Devilee P, Wijnen JT, Hes FJ, Morreau H.

Eur J Hum Genet. 2016 Jul;24(7):1089-92. doi: 10.1038/ejhg.2015.252. Epub 2015 Dec 9.

49.

Recurrent Coding Sequence Variation Explains Only A Small Fraction of the Genetic Architecture of Colorectal Cancer.

Timofeeva MN, Kinnersley B, Farrington SM, Whiffin N, Palles C, Svinti V, Lloyd A, Gorman M, Ooi LY, Hosking F, Barclay E, Zgaga L, Dobbins S, Martin L, Theodoratou E, Broderick P, Tenesa A, Smillie C, Grimes G, Hayward C, Campbell A, Porteous D, Deary IJ, Harris SE, Northwood EL, Barrett JH, Smith G, Wolf R, Forman D, Morreau H, Ruano D, Tops C, Wijnen J, Schrumpf M, Boot A, Vasen HF, Hes FJ, van Wezel T, Franke A, Lieb W, Schafmayer C, Hampe J, Buch S, Propping P, Hemminki K, Försti A, Westers H, Hofstra R, Pinheiro M, Pinto C, Teixeira M, Ruiz-Ponte C, Fernández-Rozadilla C, Carracedo A, Castells A, Castellví-Bel S, Campbell H, Bishop DT, Tomlinson IP, Dunlop MG, Houlston RS.

Sci Rep. 2015 Nov 10;5:16286. doi: 10.1038/srep16286.

50.

A novel RET/PTC variant detected in a pediatric patient with papillary thyroid cancer without ionization history.

Halkova T, Dvorakova S, Vaclavikova E, Sykorova V, Vcelak J, Sykorova P, Vlcek P, Reboun M, Katra R, Kodetova D, Schrumpf M, van Wezel T, Morreau H, Bendlova B.

Hum Pathol. 2015 Dec;46(12):1962-9. doi: 10.1016/j.humpath.2015.08.013. Epub 2015 Sep 15.

PMID:
26472164

Supplemental Content

Loading ...
Support Center